ClinicalTrials.gg
RecruitingNCT07579702STRIVE 2Updated Aug 3, 2026

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

An interventional study of Omnipod 5 System and Omnipod 6 System in Type 2 Diabetes Mellitus and Type 1 Diabetes Mellitus, sponsored by Insulet Corporation. Recruiting at 11 sites in United States. Open to participants aged 14 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Insulet Corporation · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
14 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States — 344 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Planned enrollment
986th of 2,960
200 · median 90
Started
2026
with 156 others
No phase
1,241 of 3,307
199 open now
Primary completion
2027-02
later than 207 of 477 live
Registered
3,230th of 3,307
by date

Among the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 986th largest by planned enrollment of the 2,960 interventional ones that give a count, is one of 157 that started in 2026, is one of 1,241 with no phase, reaches primary completion later than 207 of the 477 other live ones, and was the 3,230th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

344 of the 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

339 more — sign in →

All 344 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 14 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,307 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

Read the detailed description

Following a 2-week standard therapy phase for baseline data collection, participants will be randomly assigned to the order in which they receive Omnipod 6 or Omnipod 5.

After completion of the first 13-week period, participants will cross-over to the opposite system for an additional 13 weeks. An optional 4-week extension will be offered to all participants to assess the response of the Omnipod 6 System with restricted boluses

03

Conditions studied

  • Type 2 Diabetes Mellitus
  • Type 1 Diabetes Mellitus

Keywords

  • Omnipod
  • Automated Insulin Delivery
  • T2D
  • T1D
  • Type 2 Diabetes
  • Type 1 Diabetes
  • AID
04

Who can participate

Ages eligible
14 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at time of consent 14-75 years (inclusive)
  • Type 1 diabetes diagnosis for at least 6 months or type 2 diabetes diagnosis for at least 1 year, based on Investigator's clinical judgment
  • Basal/Bolus insulin delivery via multiple daily doses or insulin pump with or without automation
  • ≥ 7.5%
  • Average # of user-initiated boluses less than 4 per day over the 14 days prior to screening through review of device data or self-reported if non-pump user
  • Average # of user-initiated boluses less than 4 per day over 14 days, during Standard Therapy Phase through review of device data or self-reported if non-pump user
  • Currently using a continuous glucose monitor
  • Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic equivalents.
  • Participant agrees to provide their own insulin for the duration of the study
  • Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and/or caregiver can safely operate all study devices and can adhere to the protocol
  • Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and/or caregiver can safely operate all study devices and can adhere to the protocol
  • If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor (T2D only), or other) or weight-reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes.
  • Willing to wear the system continuously throughout the study
  • Willing and able to sign the Form (ICF) or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from adolescent participants aged \< 18 years per local regulatory requirements
  • Able to read and understand English and operate the study device in English
  • If of , willing and able to have pregnancy testing

Exclusion criteria

Exclusion Criteria:

  • Any medical condition, which in the opinion of the investigator, would put the participant at an unacceptable safety risk
  • Current or known history of coronary artery disease that is not stable with medical management per investigator judgment, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening
  • Any planned surgery during the study which could be considered major in the judgment of the investigator
  • History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered mental and/or physical status, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
  • History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness or infusion failure
  • Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement
  • Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of
  • Use of hydroxyurea
  • Plans to receive blood transfusion over the course of the study
  • Has taken systemic (oral or injectable) within 4 weeks or has had a local steroid injection (e.g. intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study
  • Has type 1 diabetes and is taking non insulin glucose lowering medication other than metformin and GLP1, in the 4 weeks prior to screening.
  • Has type 2 diabetes and is taking sulfonylureas in the 4 weeks prior to screening
  • Pregnant or lactating, or of and not on acceptable form of (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner).
  • Participation in another clinical study using an drug or device within 30-days or intends to participate in any other study during this study period
  • Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment
  • Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Omnipod 5 System

    Device: Omnipod 5 System

  • Experimental
    Omnipod 6 System

    Device: Omnipod 6 System

Interventions

  • DeviceOmnipod 5 System

    The Omnipod 5 System with the study CGM

  • DeviceOmnipod 6 System

    The Omnipod 6 System with the study CGM

06

What researchers measure

Primary outcomes

  1. Time in Range 70-180 mg/dL

    Change in CGM percent time 70-180 mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  2. Time <54 mg/dL

    Change in CGM percent time \<54 mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  3. Time <70 mg/dL

    Change in CGM percent time \<70 mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  4. Time >180 mg/dL

    Change in CGM percent time \>180 mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  5. Time in Range 70-140 mg/dL

    Change in CGM percent time 70-140 mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  6. HbA1c

    Change in HbA1c (%) between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  7. Mean sensor glucose

    Change in mean CGM glucose mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  8. Time >250 mg/dL

    Change in CGM percent time \>250 mg/dL compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

Secondary outcomes

  1. Total boluses per day

    Total blues per day will be compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  2. Total daily insulin per kg and total insulin delivered via automation

    Total daily insulin per kg and total insulin delivered via automation will be compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  3. Percentage of time in automated mode

    Percentage of time in automated mode will be compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  4. Percentage with HbA1c <7.0% and <7.5%

    Percentage with HbA1c \<7.0% and \<7.5% will be compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  5. Percentage with >= 70% time in range

    Percentage with \>= 70% time in range will be compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  6. Percentage with >= 50% time in range

    Percentage with \>= 50% time in range will be compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  7. Diabetes treatment satisfaction

    Patient Reported Outcome with treatment period comparison and baseline to Omnipod 6

    Time frame: 13 weeks

  8. System Usability

    Patient Reported Outcome Survey evaluated at the end of each 13-week period

    Time frame: 13 weeks

  9. System Opinion

    Patient Reported Outcome Survey evaluated at the end of each 13-week period

    Time frame: 13 weeks

  10. Health Related Quality of Life (HR-QOL)

    Patient Reported Outcome Survey with treatment period comparison and baseline to Omnipod 6

    Time frame: 13 weeks

  11. Hypoglycemia confidence

    Patient Reported Outcome Survey with treatment period comparison and baseline to Omnipod 6

    Time frame: 13 weeks

  12. Missed Meal - Peak glucose

    Peak glucose 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  13. Missed Meal - AUC

    AUC 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  14. Missed Meal - Time in Range

    Time in Range 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  15. Missed Meal - Percentage of Time > 180 mg/dL

    Percentage of Time \> 180 mg/dL 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  16. Missed Meal - Percentage of Time > 250 mg/dL

    Percentage of Time \> 250 mg/dL 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  17. Missed Meal - Percentage of Time <54 mg/dL

    Percentage of Time \<54 mg/dL (NI margin of 0.5%) 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  18. Missed Meal - Percentage of Time <70 mg/dL

    Percentage of Time \<70 mg/dL (NI margin of 0.5%) 4-hours post-prandial compared between Omnipod 6 and Omnipod 5

    Time frame: 13 weeks

  19. Number of severe hypoglycemic events

    Time frame: 13 weeks

  20. Number of DKA or HHS events

    Time frame: 13 weeks

  21. Other related serious adverse events

    Time frame: 13 weeks

  22. Unanticipated adverse device effects

    Time frame: 13 weeks

  23. Reportable device-related adverse events

    Time frame: 13 weeks

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

Of 177 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 29. This study's planned 9 months is below that.

Counting every sponsor, half of 2,249 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 12, 2026
StartActual
May 13, 2026
Primary completionEst.
Feb 22, 2027
CompletionEst.
Mar 24, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07579702
Responsible party
Sponsor
First posted
May 12, 2026
Start date
May 13, 2026
Primary completion
Feb 22, 2027 (estimated)
Completion
Mar 24, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Trang Ly, MBBS, PhD
Contact
APClinical@insulet.com
978-600-7000
Bonnie Dumais, RN
Contact
APClinical@insulet.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion